Due to their small population, few resources and fewer clinical trials are devoted exclusively to patients with rare kidney cancer (also call "non clear cell renal cell carcinoma" or nccRcc).
Research update from a 2018 Hackathon Team: Marvin Weinstein and Bernard Chen of Quantum Insights (Original Document Here). I go into more detail on the implications of this in a a recent blog post).
